(Q50929302)

25 March 2018

title

Tumour molecular profiling for deciding therapy-the French initiative. (English)

1 reference

25 March 2018

2

Jean-Charles Soria

0 references

author name string

Frédérique Nowak

series ordinal

1

1 reference

25 March 2018

Jean-Charles Soria

series ordinal

2

1 reference

25 March 2018

Fabien Calvo

series ordinal

3

1 reference

25 March 2018

language of work or name

English

0 references

publication date

10 July 2012

1 reference

25 March 2018

Nature Reviews Clinical Oncology

published in

1 reference

25 March 2018

volume

9

1 reference

25 March 2018

issue

8

1 reference

25 March 2018

page(s)

479-486

1 reference

25 March 2018

Cancer driver mutations in protein kinase genes

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.42

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.42

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.42

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.42

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.42

Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.42

Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.42

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.42

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.42

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.42

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.42

Current technologies for HER2 testing in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.42

Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.42

Detection of KRAS mutations in colorectal cancer by high-resolution melting analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.42

A multiplex SNaPshot assay as a rapid method for detecting KRAS and BRAF mutations in advanced colorectal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.42

KRAS analysis in colorectal carcinoma: analytical aspects of Pyrosequencing and allele-specific PCR in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.42

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.42

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.42

Epidermal growth factor receptor mutations in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.42

The epidermal growth factor receptor-L861Q mutation increases kinase activity without leading to enhanced sensitivity toward epidermal growth factor receptor kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.42

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.42

KRAS mutation status in colorectal cancer to predict response to EGFR targeted therapies: the need for a more precise definition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.42

EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.42

Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.42

Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.42

Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.42

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.42

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.42

New driver mutations in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.42

Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.42

Screening for epidermal growth factor receptor mutations in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.42

Emerging ethnic differences in lung cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.42

HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.42

KRAS and BRAF mutation analysis in metastatic colorectal cancer: a cost-effectiveness analysis from a Swiss perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.42

Clinical and economic value of screening for Kras mutations as predictors of response to epidermal growth factor receptor inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.42

Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.42

Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.42

Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.42

Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.42

Profiling critical cancer gene mutations in clinical tumor samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.42

Comprehensive next-generation cancer genome sequencing in the era of targeted therapy and personalized oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.42

Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.42

DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.42

Relative Abundance of EGFR Mutations Predicts Benefit From Gefitinib Treatment for Advanced Non–Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.42

[Five year survival for lung cancer patients managed in general hospitals]

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.42

Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.42

[Epidemiologic of primary bronchial carcinoma management in the general French hospital centers]

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22777058

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

An apoptosis methylation prognostic signature for early lung cancer in the IFCT-0002 trial.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22777058

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRCLINONC.2012.42

1 reference

25 March 2018

1 reference

25 March 2018